E-DRUG: WHO/EDM Management Changes
----------------------------------------------------------------
[original message dated 9 March 2000]
In message this morning from the Director General several new senior
staff announcements were made, among which:
Effective next Monday, 13 March, Dr Michael Scholtz becomes Special
Representative of the Director General, "charged primarily to work with the
private sector on improved access to relevant drugs and vaccines. Dr Scholtz
will be report to my office (ie, DG's office) and working closely with the
relevant cluster."
Also effective 13 March, Dr Hiro Suzuki becomes Executive Director of Health
Technology and Pharmaceuticals (HTP), in which EDM sits.
Below is Dr Suzuki's CV from the WHO web page. Also enclosed is a transition
note from Michael Scholtz which he asked that we share with all staff.